HAGEMAN-DEPENDENT FIBRINOLYSIS IN PATIENTS WITH ESSENTIAL HYPERTENSION. EFFICACY OF TREATMENT

Influence of treatment on potential plasminogen activity (PPA) and Hageman-dependent fibrinolysis (HDF) in essential hypertensive patients (EH) was investigated. In EH-II and EH-III stages patients complicated with heart failure II the activity of PPA and the intensiveness of HDF decreased, with following soluble fibrin-monomer blood complex (SFMC) accumulation. The therapy of Ramipryl, Hydrochlorothiazide and Metoprolol or Nebivolol during 1 month and bacterium drugs (2 weeks) administration didn’t cause PPA and HDF normalization, but significantly improved their activity with simultaneous blood amount of SFMC reducing.